Top in women's health: Elinzanetant curbs hot flashes; hormone therapy boosts weight loss
Women reported a significantly lower frequency of moderate to severe menopausal vasomotor symptoms while taking elinzanetant vs. placebo, according to the results of a phase 3 trial.
After seeing positive results from the OASIS 1, 2 and 3 trials, Bayer plans to submit study data for approval and marketing authorizations.
It was the top story in women’s health last week.
In another top story, study results showed that postmenopausal women taking semaglutide — marketed as Wegovy by Novo Nordisk — in combination with hormone therapy experienced greater weight loss than women taking semaglutide by itself.
Read these and more top stories in women’s health below:
Elinzanetant significantly reduces menopausal hot flash frequency
Once-daily oral elinzanetant was associated with significantly reduced frequency of moderate to severe menopausal vasomotor symptoms compared with placebo, according to topline results from the OASIS 3 study. Read more.
Hormone therapy may boost weight loss for postmenopausal women on semaglutide
Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with semaglutide, according to cohort study results published in Menopause. Read more.
Surveillance methods lead to maternal mortality variations, possible misclassifications
Differences in U.S. cause of death surveillance methods may cause variations in currently high reported maternal mortality rates, researchers reported in the American Journal of Obstetrics & Gynecology. Read more.
Term pregnancy, vaginal delivery possible after uterine fibroid radiofrequency ablation
Women who underwent radiofrequency ablation for uterine fibroids had similar rates of full-term pregnancy, vaginal delivery and miscarriage as observed with myomectomy, researchers reported in Obstetrics & Gynecology. Read more.
No reproductive advantage with single- vs. double-layer closure after cesarean section
Researchers observed no superiority in future reproductive or obstetric outcomes with double-layer vs. single-layer uterine closure after a first cesarean section. Read more.